<p>Respiratory Syncytial Virus (RSV) belongs to the Orthopneumovirus genus within the Pneumoviridae family. It includes human RSV, bovine RSV, and murine pneumonia virus. Human RSV has two main subtypes, A and B, which differ primarily due to antigenic drift and duplications in the RSV-G gene, along with genome-wide sequence variations in RSV-F.</p>
<p>&nbsp;</p>
<p>RSV spreads through respiratory droplets from coughing, sneezing, or kissing, or by touching contaminated surfaces and then touching the eyes, nose, or mouth. The virus can survive for hours on hard surfaces but only for a short time on soft ones. Children, especially in daycare or school settings, are frequently exposed to RSV and can transmit it to family members. Nearly all children will have had an RSV infection by age 2.</p>
<h2><strong>Respiratory Syncytial Virus Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Respiratory Syncytial Virus in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Respiratory Syncytial Virus Incident Cases</li>
<li>Age-specific Incident Cases</li>
<li>Severity-specific Respiratory Syncytial Virus Incident Cases in Children</li>
<li>Severity-specific Respiratory Syncytial Virus Incident Cases in Adults</li>
<li>Visit-specific Respiratory Syncytial Virus Incident Cases</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Respiratory Syncytial Virus Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, there were approximately 8.6 million incident cases of Respiratory Syncytial Virus (RSV) across the 7MM.</li>
<li>The US accounted for around 56% of the total RSV cases.</li>
<li>RSV incidence was highest among children under 5 years, accounting for nearly 50% of all cases in the 7MM.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market"><span style="text-decoration: underline;"><strong>Respiratory Syncytial Virus Market</strong></span></a></h2>
<p>The total Respiratory Syncytial Virus Market Size in the 7MM was around USD 1,300 million in 2023.</p>
<h2>RSV Market Drivers:</h2>
<ul>
<li>Growing awareness of RSV as a major health issue, especially for infants and young children.</li>
<li>Increased focus on prevention, including vaccine development.</li>
<li>Strong patient advocacy driving awareness of RSV prevention.</li>
<li>Rising demand for effective treatments due to high unmet needs.</li>
<li>Advancements in early diagnostic tools.</li>
</ul>
<h2>RSV Market Barriers:</h2>
<ul>
<li>Limited preventive options and vaccines.</li>
<li>Low awareness among parents about RSV risks and prevention.</li>
<li>Challenges in creating effective treatments for all age groups.</li>
<li>High treatment costs limiting access.</li>
<li>Slow regulatory approval processes for new therapies.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight"><span style="text-decoration: underline;"><strong>Respiratory Syncytial Virus Emerging Drugs</strong></span></a></h2>
<p>The emerging drugs of the Respiratory Syncytial Virus market are</p>
<ul>
<li>VAC 18193&nbsp;</li>
<li>mRNA-1345</li>
</ul>
<p>And others.</p>
<h2><strong>Respiratory Syncytial Virus Key Players</strong></h2>
<p>The key players in the Respiratory Syncytial Virus market are</p>
<ul>
<li>Bavarian Nordic</li>
<li>GlaxoSmithKline</li>
<li>Janssen</li>
<li>Sanofi</li>
<li>AstraZeneca</li>
<li>Moderna</li>
</ul>
<p>And others.</p>

Respiratory Syncytial Virus Market

Respiratory Syncytial Virus Market Infographics

Respiratory Syncytial Virus Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape